HC Wainwright Has Positive Outlook for UTHR FY2026 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – HC Wainwright upped their FY2026 earnings per share (EPS) estimates for United Therapeutics in a research report issued on Tuesday, March 31st. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $27.39 per share for the year, up from their previous forecast of $25.23. HC Wainwright currently has a “Buy” rating and a $660.00 target price on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q4 2026 earnings at $7.12 EPS, FY2027 earnings at $39.79 EPS, FY2028 earnings at $39.83 EPS, FY2029 earnings at $41.54 EPS and FY2030 earnings at $47.58 EPS.

Several other brokerages also recently commented on UTHR. Bank of America upped their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research report on Tuesday. TD Cowen boosted their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $586.00.

United Therapeutics Price Performance

United Therapeutics stock opened at $564.81 on Friday. The firm’s 50 day simple moving average is $506.70 and its 200-day simple moving average is $478.68. The company has a market cap of $24.76 billion, a P/E ratio of 20.24, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter last year, the business posted $6.19 EPS. United Therapeutics’s revenue was up 7.4% on a year-over-year basis.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 361,820 shares of company stock worth $182,730,910 over the last ninety days. 10.30% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP grew its stake in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics during the 3rd quarter valued at about $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics during the 4th quarter valued at about $293,418,000. Invesco Ltd. grew its stake in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares in the last quarter. Finally, Avoro Capital Advisors LLC grew its stake in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 Tyvaso (IPF) data — the trial met its primary endpoint, supporting potential near‑term revenue upside from an expanded label and underpinning recent optimism. United Therapeutics reports positive results for lung drug
• Positive Sentiment: HC Wainwright raised price target and lifted multi‑year EPS forecasts (now Buy, $660 PT) and other brokers have moved targets higher — analyst upgrades increase buy-side conviction and support a higher valuation range. United Therapeutics Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Strong earnings‑surprise history and bullish earnings outlook — coverage notes (e.g., Zacks) highlight United Therapeutics’ track record of beating estimates, increasing the probability of another upside surprise at the next report. Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Elevated options activity — traders are positioning around the clinical news and upcoming earnings, which can amplify intraday volatility but is not a direct fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage/valuation pieces and peer comparisons are proliferating — these shape expectations for how Tyvaso lifts long‑term value but won’t themselves change fundamentals. (See Zacks comparison with Catalyst (CPRX) and valuation write‑ups.) CPRX or UTHR: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Insider selling by senior executives (CEO, EVP, CFO) — multi‑million dollar disposals under 10b5‑1 plans may be read as profit‑taking and can add short‑term selling pressure despite being pre‑arranged. Rothblatt SEC Filing (Example)

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.